Mapping the vitiligo patient journey: from awareness to treatment or coping strategies
Authors:
Open Access
- 7 January 2025
- journal article
- editorial
- Published by Frontiers Media SA in Frontiers in Rehabilitation Sciences
- Vol. 5, 1511053
Abstract
1. IntroductionDermatology encompasses over 3,000 distinct diseases, yet comprehensive data capturing the full patient journey—from onset to diagnosis and treatment—remains scarce.1 Traditional patient journey maps, where available, often depict linear progressions within healthcare settings, oversimplifying the experience. These models frequently fail to reflex the non-linear, and cyclical nature of chronic conditions like vitiligo.Vitiligo, a chronic autoimmune disorder characterized by unpredictable skin depigmentation, affects approximately 1% of the global population, with prevalence ranging from 0.1% to 2.0% depending on the region.2 Despite recent advancements in the understanding and treatment of vitiligo, patients frequently encounter significant challenges in navigating their care journey.3 While clinical advancements have improved treatment options, a gap remains in understanding how patients experience and navigate their care journeys.The Vitiligo Patient Journey Map (VPJM) was developed to bridge this gap. It offers a structured view of the patient’s journey, highlighting critical touchpoints and decision-making moments that influence outcomes. Rooted in mixed-methods research, the VPJM aims to guide clinicians, empower patients, and inform health policy to create a more patient-centered approach to care.2. Discussion2.1 MethodologyThe VPJM was developed using a rigorous mixed-methods approach.4 This included the analysis of 982 electronic patient records from a proprietary health record system, Vitiligo CloudBank (formerly Cloud MRM),5 alongside an online survey of 532 patients. The patient records, spanning 2012 to 2020, were accessed through the system’s admin panel in January 2021. These de-identified records contained detailed data on vitiligo diagnoses, treatment specifics, and follow-up outcomes. Data extraction, facilitated by the system’s built-in export feature into Excel, captured variables such as patient age, age at onset, body surface area (BSA) affected, Fitzpatrick skin type (I-VI), dates of updates, and types and numbers of treatments prescribed. Statistical analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA).The survey, based on the previously published Vitiligo Questionnaire, Version 4.0, consisted of 40 questions across seven dimensions.12 Conducted from September 12 to November 20, 2021, it was emailed to over 21,500 potential participants worldwide. Respondents began with a brief screener to collect basic demographics, confirm a vitiligo diagnosis, and obtain consent. Of the 889 individuals who passed the screening, 532 completed the full 20-minute survey. No personally identifiable information was collected at any stage. Responses were coded and analyzed using NVivo for Mac (Lumivero, Denver, CO, USA). To visualize the patient journey, a medium-fidelity digital wireframe was created using Miro, an online whiteboard tool (Los Angeles, CA, USA). The map was structured along an X-axis with three cardinal points—“White Spot,” “Beautiful,” and “Spotless”—representing phases of the journey characterized by distinct patient experiences and emotions. An initial Y-axis, intended to depict potential causes or triggers of vitiligo, was later omitted to streamline the design.The prototype underwent multiple iterations, with input from a team of 11 experts and three dermatologists, experienced in treating vitiligo. Consensus was achieved on the interdependencies of each element before advancing the design. This methodology allowed us to capture a wide range of patient experiences, from initial symptom recognition to long-term management strategies.2.2. Key FindingsOur analysis revealed consistent demographic patterns across both data sources. The median ages were 42 years (medical records) and 37 years (survey), with 51%-53% of participants being female in both groups. The median age at diagnosis was 28 and 32 years, with an average disease duration of 13 and 11 years, respectively. Additionally, 38%-32% of patients reported a known family history of vitiligo. The ethnic composition in the medical records was 3% Latino, 8% Asian, 9% Black, 69% White, and 11% multiracial, while the survey did not include ethnicity-specific questions.Clinicians estimated a median body surface area (BSA) affected by vitiligo of 4.9%. Notably, 51.9% of patients had more than 5% BSA affected, likely reflecting a higher propensity for patients with more noticeable lesions to seek medical attention. Of all cases, 12% were minor or stable, requiring little to no therapeutic intervention and resulting in no significant sequelae. A third of the patients had undergone an average of 6.2 different treatments over the course of managing their condition. These interventions included phototherapy (UVA, UVB, intense pulse light systems), topical and systemic treatments (all off-label), depigmentation and camouflage techniques, and various supplements (vitamins, minerals, plant extracts). Disease progression varied significantly among the medical records: 6% of participants experienced no progression, 32% reported slow progression, while the majority faced medium to rapid progression. Over 40% of respondents had been initially misdiagnosed, with some variation in the rate across countries. Care was fragmented, with patients consulting an average of 2.3 specialists over 7.8 months—significantly shorter than the 2.4 years reported in the VALIANT study.6 Patients had also tried an average of 5.9 treatments in total. Diagnosis and treatment timelines varied geographically, ranging from days to several years.Treatment adherence posed a significant challenge. While 45% of survey respondents reported taking weeklong treatment breaks, the actual rate of non-adherence is likely higher. The primary reason cited was a lack of noticeable improvement after three months. Some patients discontinued...Keywords
This publication has 11 references indexed in Scilit:
- The dermatology patient journey from initial consultation to diagnosisJournal of the European Academy of Dermatology and Venereology, 2023
- Mental Health and Psychosocial Quality-of-Life Burden Among Patients With VitiligoJAMA Dermatology, 2023
- Exploring the natural and treatment history of vitiligo: perceptions of patients and healthcare professionals from the global VALIANT studyBritish Journal of Dermatology, 2023
- Prevalence of Vitiligo Among Adults in the United StatesJAMA Dermatology, 2021
- Design thinking as an approach for innovation in healthcare: systematic review and research avenuesBMJ Innovations, 2020
- Creation of a Patient-Centered Journey Map to Improve the Patient Experience: A Mixed Methods ApproachMayo Clinic Proceedings: Innovations, Quality & Outcomes, 2019
- Patient-reported outcomes: A 5-year long study reveals previously unreported therapeutic, demographic, socio-economic, and other correlations in vitiligoDermatologic Therapy, 2018
- Functional nutrition as integrated approach in vitiligo managementDermatologic Therapy, 2018
- Human-centred design in global health: A scoping review of applications and contextsPLOS ONE, 2017
- Maintenance Therapy of Adult Vitiligo with 0.1% Tacrolimus Ointment: A Randomized, Double Blind, Placebo–Controlled StudyJournal of Investigative Dermatology, 2015